Michael Lever1, Wendy Atkinson, Peter M George, Stephen T Chambers. 1. Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand. michael.lever@chmeds.ac.nz
Abstract
OBJECTIVES: Does abnormal betaine excretion persist? DESIGN AND METHODS: Patients (10) with abnormal excretion in 1998 were recalled in 2005. Subsequent urine samples were collected on 4 days from persistently abnormal subjects. RESULTS: Half the 1998 abnormal patients were abnormal in 2005. Only 1/20 controls was abnormal (p=0.015). All patients with abnormal excretion in 1998 and 2005 had abnormal excretion on successive days while no controls did. CONCLUSIONS: High betaine excretion may be chronic and a health risk.
OBJECTIVES: Does abnormal betaine excretion persist? DESIGN AND METHODS: Patients (10) with abnormal excretion in 1998 were recalled in 2005. Subsequent urine samples were collected on 4 days from persistently abnormal subjects. RESULTS: Half the 1998 abnormal patients were abnormal in 2005. Only 1/20 controls was abnormal (p=0.015). All patients with abnormal excretion in 1998 and 2005 had abnormal excretion on successive days while no controls did. CONCLUSIONS: High betaine excretion may be chronic and a health risk.
Authors: Michael Lever; Peter M George; Jane L Elmslie; Wendy Atkinson; Sandy Slow; Sarah L Molyneux; Richard W Troughton; A Mark Richards; Christopher M Frampton; Stephen T Chambers Journal: PLoS One Date: 2012-05-23 Impact factor: 3.240
Authors: Michael Lever; Sandy Slow; David O McGregor; Warwick J Dellow; Peter M George; Stephen T Chambers Journal: Cardiovasc Diabetol Date: 2012-07-11 Impact factor: 9.951
Authors: Hall Schartum-Hansen; Per M Ueland; Eva R Pedersen; Klaus Meyer; Marta Ebbing; Øyvind Bleie; Gard F T Svingen; Reinhard Seifert; Bjørn E Vikse; Ottar Nygård Journal: PLoS One Date: 2013-08-06 Impact factor: 3.240